An experimental therapy may help remove harmful antibodies that reduce the effectiveness of factor replacement therapies in hemophilia A, potentially offering a new way to overcome one of the most significant complications of standard care. The therapy uses chimeric autoantibody receptor T cells, or CAAR-T cells. These are…
News
In boys and men with severe hemophilia A, starting prophylaxis — preventive treatment given regularly to reduce bleeding — early and maintaining regular physical activity were each linked to a lower risk of hemophilic arthropathy, a progressive form of joint damage caused by repeated bleeding, according to a real-world…
A young woman who sought emergency care for severe pain and swelling of her left hand five weeks after giving birth was ultimately diagnosed with acquired hemophilia A — caught early enough that she did not require surgery. That’s according to a new report detailing the woman’s case, which,…
Dental treatments can be performed safely in people with hemophilia when proper medical precautions are followed, according to a review of studies worldwide. Most studies reported that raising the dose of factor replacement therapies to 30% to 50% of normal before treatment helped prevent excessive bleeding. With this…
Testing levels of thrombin — an enzyme that helps blood clot — in people with acquired hemophilia A could help doctors fine-tune care for these patients when both clot-promoting and blood-thinning medications are used. That’s the conclusion drawn by researchers in the Netherlands, who found that thrombin testing in…
The World Health Organization (WHO) executive board approved a resolution designed to improve access to diagnostic testing and treatment for people with hemophilia and other bleeding disorders. The resolution calls on WHO member states to take actions to improve access to quality care for people with bleeding disorders. It…
Pfizer said the U.S. Food and Drug Administration (FDA) will review the company’s request to expand approval of its preventive treatment Hympavzi (marstacimab) to cover all people with hemophilia A or B ages 6 and older. Hympavzi is FDA-approved to treat hemophilia A and B in patients ages…
While nearly one-third of people living with hemophilia are female, a new global survey reveals that many of these patients remain undiagnosed due to systemic healthcare barriers and social stigma. Researchers representing the World Federation of Hemophilia (WFH) are calling for a coordinated effort to improve diagnostic access…
A single infusion of Hemgenix (etranacogene dezaparvovec-drlb) helped boost levels of factor IX (FIX), the clotting protein missing in hemophilia B, in many patients who already had antibodies against the viral carrier, according to new trial data. The findings suggest the gene therapy may benefit a broader group of…
People living with hemophilia face a 46% higher risk of bone fractures than the general population, with that risk increasing for those with severe disease or a history of treatment-blocking antibodies. These are the findings of a large-scale Canadian study that highlights a growing health concern for patients as…
Recent Posts
- A recipe of support for parents new to a hemophilia diagnosis
- New CAAR-T therapy may eliminate hemophilia A treatment blockers: Study
- A little reminder about how to pay better attention to bleeds
- When ‘difficult’ shoes make life with hemophilia easier for my husband
- Growing up before treatments for hemophilia were safe, part 3